The abstract is read at the publisher; the summary is JClub's.
Vorasidenib produced progressive MRI tumor shrinkage in 54 grade 2 IDH1/2-mutant astrocytomas and oligodendrogliomas, with median volume reductions reaching -55.5% by cycle 18.
- Why it matters: Clinicians need predictors of who benefits most from vorasidenib in residual or recurrent grade 2 IDH1/2-mutant gliomas, including effects on seizure control.
- What they did: In a prospective single-centre study, longitudinal 2D/3D volumetric MRI and seizure outcomes were tracked in patients treated with vorasidenib, and regression models explored factors linked to MRI response.
- The result: The ORR (CR+PR+MR) was 28%, and 9/12 (75%) baseline seizure patients achieved ≥50% reduction or seizure freedom; MRI response correlated with early treatment initiation and early seizure reduction.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.